Skip to main content
Article thumbnail
Location of Repository

Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison

By A. J. Sutton, W. John Edmunds and O. N. Gill

Abstract

Background\ud In England and Wales where less than 1% of the population are Injecting drug users (IDUs), 97% of HCV reports are attributed to injecting drug use. As over 60% of the IDU population will have been imprisoned by the age of 30 years, prison may provide a good location in which to offer HCV screening and treatment. The aim of this work is to examine the cost effectiveness of a number of alternative HCV case-finding strategies on prison reception\ud \ud Methods\ud A decision analysis model embedded in a model of the flow of IDUs through prison was used to estimate the cost effectiveness of a number of alternative case-finding strategies. The model estimates the average cost of identifying a new case of HCV from the perspective of the health care provider and how these estimates may evolve over time.\ud \ud Results\ud The results suggest that administering verbal screening for a past positive HCV test and for ever having engaged in illicit drug use prior to the administering of ELISA and PCR tests can have a significant impact on the cost effectiveness of HCV case-finding strategies on prison reception; the discounted cost in 2017 being £2,102 per new HCV case detected compared to £3,107 when no verbal screening is employed.\ud \ud Conclusion\ud The work here demonstrates the importance of targeting those individuals that have ever engaged in illicit drug use for HCV testing in prisons, these individuals can then be targeted for future intervention measures such as treatment or monitored to prevent future transmission.\ud \u

Topics: HN
Publisher: BioMed Central Ltd.
Year: 2006
OAI identifier: oai:wrap.warwick.ac.uk:555

Suggested articles

Citations

  1. (2002). A: Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess
  2. (1999). Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. BMJ doi
  3. (2004). Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. doi
  4. (2000). go for HCV antigen testing? Commun Dis Public Health
  5. Guidance on the use of Ribavirin and Interferon Alpha for Hepatitis C. Volume 14. National Institute for Clinical Excellence;
  6. Hartnoll R: Surveillance of hepatitis C infection among injecting drug users in the European Union. In Hepatitis C and injecting drug use: impact, costs and policy options Edited by: doi
  7. (2005). Health Protection Agency Centre for Infections: Hepatitis C in England: The First Health Protection Agency Annual Report. doi
  8. (2004). JD: Hepatitis C infection and incarcerated populations. doi
  9. (2004). ME: Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf) doi
  10. (2006). Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect doi
  11. (2005). National Public Health Service for Wales, Ireland CDSCN, CRDHB, UASSG: Shooting Up; Infections among injecting drug users in the United Kingdom 2004, An update:
  12. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2458/6/170/pre pub
  13. Natural history, treatment and prevention of hepatitis C in injecting drug users; an overview. In Hepatitis C and injecting drug use: impact, costs and policy options Edited by: doi
  14. (2004). Netten A: Unit Costs of Health and Social Care Personal Social Services Research Unit;
  15. (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep doi
  16. (1998). Self-report among injecting drug users: a review. Drug Alcohol Depend doi
  17. (2003). The Green Book, Apprasial and Evaluation in Central Government
  18. (2003). Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci
  19. (2006). What drug policies cost: estimating government drug policy expenditures. Addiction doi
  20. (1999). What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? doi
  21. (2001). Wiessing L: A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction doi
  22. (2002). Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect doi
  23. (2003). WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.